# Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia

> **NCT00108758** · PHASE2 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 23 (actual)

## Conditions studied

- Congenital Bleeding Disorder
- Haemophilia A With Inhibitors
- Haemophilia B With Inhibitors

## Interventions

- **DRUG:** activated recombinant human factor VII

## Key facts

- **NCT ID:** NCT00108758
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2005-11
- **Final completion:** 2005-11
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2017-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00108758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00108758, "Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00108758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*